Aimmune Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, AIMT, Aimmune Therapeutics Inc, priceseries

Aimmune Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
34.56
Close
34.49
High
34.56
Low
34.48
Previous Close
34.59
Daily Price Gain
-0.10
YTD High
42.00
YTD High Date
Feb 20, 2018
YTD Low
9.77
YTD Low Date
Jul 7, 2016
YTD Price Change
10.39
YTD Gain
43.11%
52 Week High
34.59
52 Week High Date
Oct 9, 2020
52 Week Low
34.28
52 Week Low Date
Sep 25, 2020
52 Week Price Change
0.19
52 Week Gain
0.55%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
18.56
Jul 26. 2017
21.24
25 Trading Days
14.44%
Link
LONG
Nov 8. 2017
30.94
Dec 4. 2017
36.23
17 Trading Days
17.09%
Link
LONG
Jan 30. 2019
22.86
Feb 13. 2019
24.07
10 Trading Days
5.30%
Link
LONG
Oct 23. 2019
25.79
Nov 7. 2019
27.61
11 Trading Days
7.05%
Link
LONG
Dec 3. 2019
28.59
Jan 9. 2020
33.38
25 Trading Days
16.75%
Link
LONG
Apr 6. 2020
14.08
Apr 16. 2020
15.27
7 Trading Days
8.45%
Link
Company Information
Stock Symbol
AIMT
Exchange
NasdaqGS
Company URL
http://www.aimmune.com
Company Phone
(650) 614-5220
CEO
Stephen George Dilly
Headquarters
California
Business Address
8000 MARINA BOULEVARD, SUITE 300, BRISBANE, CA 94005-1884
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001631650
About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy (CODIT) system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.

Description

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading